Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 5 , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/genetics , Thrombocytopenia/diagnosis , Thrombocytopenia/genetics , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , Blood Platelets/pathology , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/mortality , Platelet Count , Prognosis , Severity of Illness Index , Thrombocytopenia/complications , Thrombocytopenia/mortalityABSTRACT
We report a case of a successful mobilization and harvest of the peripheral blood stem cells (PBSCs) in imatinib-pretreated and nilotinib treated 52-year-old woman diagnosed with Philadelphia chromosome-positive and BCR-ABL (b2a2) positive chronic phase CML in 2/2002. She failed interferon-alfa and imatinib treatment. She achieved her first complete molecular remission after 16 months of nilotinib treatment and later on was mobilized with filgrastim at a dose of 10 ug/kg/day applied subcutaneously once daily. The total number of 2.98 x 10(6) CD34+ cells/kg was harvested on the fourth day of the mobilization. The autologous graft of the stem cells was cryopreserved and tested for the residual disease: the FISH revealed negative results and the RT-PCR was positive (BCR-ABL/ABL ratio 0,0017 in RQ-PCR). To our knowledge, this is the first report of successful PBSC harvest in a patient significantly pretreated with imatinib and nilotinib.
